We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · August 27, 2014

DLBCL and Indolent B-Cell Malignancies Can Be Effectively Treated With Anti-CD19 CAR T Cells

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
J. Clin. Oncol 2014 Aug 25;[EPub Ahead of Print], JN Kochenderfer, ME Dudley, SH Kassim, RPT Somerville, RO Carpenter, M Stetler-Stevenson, JC Yang, GQ Phan, MS Hughes, RM Sherry, M Raffeld, S Feldman, L Lu, YF Li, LT Ngo, A Goy, T Feldman, DE Spaner, ML Wang, CC Chen, S M Kranick, A Nath, DN Nathan, KE Morton, MA Toomey, SA Rosenberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading